Hypertension, or high blood pressure, is a global health crisis, affecting over 1.28 billion adults and contributing to millions of deaths annually through complications like heart disease, stroke, and kidney failure. While lifestyle changes and medications can manage the condition, they rarely address the underlying genetic predispositions that contribute to hypertension. Recent advancements in genetic science, particularly CRISPR-Cas9 gene editing technology, offer new hope for tackling the root causes of this pervasive condition. This article explores the potential of CRISPR technology to revolutionize hypertension treatment by targeting its genetic roots, the challenges involved, and the ethical considerations of applying gene editing in this context.
